Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
opioid dependence
Biotech
Eolas regains opioid use disorder drug abandoned by AstraZeneca
AZ ended work on the orexin 1 receptor antagonist in November after a phase 2 study identified a “potential drug-drug interaction" with itraconazole.
James Waldron
Jul 10, 2025 9:33am
Tris' opioid alternative reduces post-surgery pain in phase 3
Jan 22, 2025 8:30am
Pain relief without opioids' ill effects? New molecules found
Oct 3, 2022 3:55pm
ATAI, DemeRx pursue 'neurochemical reset' for addiction
Jan 24, 2020 9:00am
Johns Hopkins unveils $17M center for psychedelics research
Sep 6, 2019 2:20pm
Scorpion toxin could inspire non-opioid pain treatments
Aug 23, 2019 8:45am